**Hazardous Substances Assessment**

|  |  |  |  |
| --- | --- | --- | --- |
| **1**. Activity / role to be assessed | SARS-CoV-2 Antigen Rapid Qualitative Test – Extraction Solution | **2**. Date of risk assessment  | 28/1/2021 |
| **3**.Person undertaking assessment | Louise Smith | **4**. Location of assessment | Springfield School |

Use the Material Safety Data Sheet for the substance to help complete the assessment. Substances which are similar and do not present different hazards maybe grouped together for assessment.

(Frequency of use = Daily-**D,** Weekly-**W,** Rarely-**R.**) (Entry Route – Inhalation = **I,** Direct contact = **DC,** Ingestion =**ING**)

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Substance** | **Used for:** | **Usage D, W, R** | **Hazard** | **Entry route****I, DC, ING** | What is the potential harm & to whom? | **W.E.L? Y/N (note 6)** | **Current controls** | **Risk rating note 5** | **Further action to reduce risk** |
| Extraction solution which comes with the lab test kit contains the following components: NA2HPO4  (disodium hydrogen phosphate), NaH2PO4 (sodium phosphate monobasic), NaCl (Sodium Chloride  | Used in the Lateral Flow Test process for the extraction of specimen. | D | These components do not have any hazard labels associated with them. | I, DC, ING | The manufacturer states that there are no hazards anticipated under conditions of use as described in other product literature. This is the case for exposure to: eye, skin, inhalation, ingestion, chronic toxicity, reproductive and developmental toxicity, carcinogenicity, and medical conditions aggravated by exposure |  | * **PPE**: nitrile gloves which meet the Regulation (EU) 2016/425 to be used at all times when handling the extraction solution. Safety glasses with side shields which are tested and approved under appropriate government standards to be worn at all times when handling the extraction solution. Impervious clothing to be worn to protect the body from splashes or spillages.
* **Environmental**: do not let product enter drains
 | **LOW** | **Spillages**: wipe surfaces which the solution has been spilt on and dispose of cleaning material in line with the current clinical waste disposal procedures. |

**5. Risk rating**

Identify the level of toxicity of the substance across the top of the table, then identify the exposure level (side of table) and work across the table to meet the level of toxicity identified. This is the risk rating. Exposure is the level of the substance to which people are exposed. Frequency of use and entry routes must be considered to determine the level of exposure.

|  |  |
| --- | --- |
|  | **Risk of process/substance** |
|  | **Toxicity ** | **Low** – Corrosive, irritant, harmful, Category 1 pathogen | **Toxic** – toxic, assigned WEL, category 3 pathogen | **Very toxic –** very toxic, carcinogens, sensitisers, assigned a WEL cat 3 or 4 pathogen |
| **Exposure ** | **High** | **Medium** | **High** | **High** |
| **Significant** | **Low** | **Medium** | **High** |
| **Limited** | **Low** | **Low** | **Medium** |

|  |  |  |
| --- | --- | --- |
| **Risk rating** | **Description** | **Action Priority** |
| **High**  | Exposure is likely or very likely resulting in serious health effects. | Urgent action required to reduce the risk |
| **Medium** | Exposure is possible and could result in harm to health | Medium  |
| **Low** | Exposure is limited and potential risk to health low where control measures are in place.  | Low priority.  |

**6. Workplace Exposure Limit (WEL).** Where workplace exposure limits are in place for a substance it may be necessary to undertake monitoring to ensure the limits are not exceeded.

|  |  |  |
| --- | --- | --- |
| Substance  | WEL | What monitoring of actual exposure is required? Attach plan for monitoring. |
|  |  |  |
|  |  |  |

**7. Training and instruction**

|  |  |  |
| --- | --- | --- |
| What training and instruction is required? | Who requires training?(groups or individuals where necessary) | Frequency of training  |
|  |  |  |
|  |  |  |
|  |  |  |

**8. Health Surveillance**

It may be necessary to discuss the nature and frequency of Health Surveillance with the Occupational Health Unit

|  |  |  |
| --- | --- | --- |
| What health surveillance is necessary? | Who will carry out health surveillance? | Frequency of surveillance? |
|  |  |  |
|  |  |  |
|  |  |  |

**9. Additional Hazards**

Tick if any substance assessed impacts any of the areas below:

|  |  |  |
| --- | --- | --- |
| **Manual Handling** | **Fire** | **Individual person such as Young Person, New/ Expectant Mother or Service User** |
|  |  |  |

If any are ticked a specific risk assessment must be completed for that hazard.

**10. Further Action -** Indicate any additional action required to reduce/eliminate risk and time scale for implementation

**11. Assessment**

|  |  |  |  |
| --- | --- | --- | --- |
| Signature of Assessor | Date assessed | Methods of communication | Date of communication |
| L Smith | 01.02.2021 | Emailed to all Staff  | 02.02.2021 |

**Review**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Date  | Reviewed by | Action required | Method of communication | Date of communication |
|  |  |  |  |  |
|  |  |  |  |  |

**12. Communication and** **Review**

This assessment should be communicated to all employees and relevant persons who may come into contact with the substances/process being assessed. The Safety Data Sheet must be readily available to those involved in the process or using the substance. The assessment must be reviewed at least every 5 years or where circumstances change.